Predictors of Hospitalized Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease

Background and Aim Exacerbations of chronic obstructive pulmonary disease (COPD) carry significant consequences for patients and are responsible for considerable health-care costs—particularly if hospitalization is required. Despite the importance of hospitalized exacerbations, relatively little is known about their determinants. This study aimed to analyze predictors of hospitalized exacerbations and mortality in COPD patients. Methods This was a retrospective population-based cohort study. We selected 900 patients with confirmed COPD aged ≥35 years by simple random sampling among all COPD patients in Cantabria (northern Spain) on December 31, 2011. We defined moderate exacerbations as events that led a care provider to prescribe antibiotics or corticosteroids and severe exacerbations as exacerbations requiring hospital admission. We observed exacerbation frequency over the previous year (2011) and following year (2012). We categorized patients according to COPD severity based on forced expiratory volume in 1 second (Global Initiative for Chronic Obstructive Lung Disease [GOLD] grades 1–4). We estimated the odds ratios (ORs) by logistic regression, adjusting for age, sex, smoking status, COPD severity, and frequent exacerbator phenotype the previous year. Results Of the patients, 16.4% had ≥1 severe exacerbations, varying from 9.3% in mild GOLD grade 1 to 44% in very severe COPD patients. A history of at least two prior severe exacerbations was positively associated with new severe exacerbations (adjusted OR, 6.73; 95% confidence interval [CI], 3.53–12.83) and mortality (adjusted OR, 7.63; 95%CI, 3.41–17.05). Older age and several comorbidities, such as heart failure and diabetes, were similarly associated. Conclusions Hospitalized exacerbations occurred with all grades of airflow limitation. A history of severe exacerbations was associated with new hospitalized exacerbations and mortality.

[1]  N. Siafakas,et al.  Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions? , 2004, Respiratory medicine.

[2]  R. Zuwallack,et al.  An official American Thoracic Society/European Respiratory Society statement: research questions in COPD , 2015, European Respiratory Review.

[3]  B. Celli,et al.  Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[4]  Courtney Crim,et al.  Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. , 2014, American journal of respiratory and critical care medicine.

[5]  M. Miravitlles,et al.  Factors Associated with Increased Risk of Exacerbation and Hospital Admission in a Cohort of Ambulatory COPD Patients: A Multiple Logistic Regression Analysis , 2000, Respiration.

[6]  D. Niewoehner,et al.  Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.

[7]  M. Martínez-García,et al.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.

[8]  H. Thompson,et al.  Prognosis in chronic obstructive pulmonary disease. , 1973, The American review of respiratory disease.

[9]  A. Adelman Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. , 1999, The Journal of family practice.

[10]  N. Calaf,et al.  [Risk factors for mortality in chronic obstructive pulmonary disease]. , 2007, Archivos de bronconeumologia.

[11]  Paul A Estabrooks,et al.  Practical Clinical Trials for Translating Research to Practice: Design and Measurement Recommendations , 2005, Medical care.

[12]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[13]  J. Wedzicha,et al.  Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease , 2013, BMC Medicine.

[14]  A. Pont,et al.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.

[15]  A. Hansell,et al.  COPD prevalence in a random population survey: a matter of definition , 2007, European Respiratory Journal.

[16]  C. Jenkins,et al.  Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study , 2009, Respiratory research.

[17]  Z. Tong,et al.  Predictors of exacerbation frequency in chronic obstructive pulmonary disease , 2014, European Journal of Medical Research.

[18]  S. Ramsey,et al.  The economic burden of COPD. , 2000, Chest.

[19]  J. Wedzicha,et al.  COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.

[20]  D. A. Luke,et al.  An Odd Measure of Risk: Use and Misuse of the Odds Ratio , 2001, Obstetrics and gynecology.

[21]  Toru Oga,et al.  Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.

[22]  P. Casañ,et al.  Factores de riesgo de mortalidad en la EPOC , 2007 .

[23]  J. Soriano,et al.  Spanish guideline for COPD (GesEPOC). Update 2014. , 2014, Archivos de bronconeumologia.

[24]  H. Lamberts,et al.  The International Classification of Primary Care (ICPC): new applications in research and computer-based patient records in family practice. , 1996, Family practice.

[25]  D. Mannino,et al.  Lung function impairment, COPD hospitalisations and subsequent mortality , 2011, Thorax.

[26]  Robert Wise,et al.  Predictors of mortality in patients with emphysema and severe airflow obstruction. , 2006, American journal of respiratory and critical care medicine.

[27]  N. Persaud,et al.  External validity: the neglected dimension in evidence ranking. , 2006, Journal of evaluation in clinical practice.

[28]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[29]  N. Anthonisen,et al.  Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[30]  T. Seemungal,et al.  COPD exacerbations: defining their cause and prevention , 2007, The Lancet.

[31]  C. Lavie,et al.  Benefits of cardiac rehabilitation and exercise training. , 2000, Chest.

[32]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[33]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[34]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[35]  Cesar G Victora,et al.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study , 2005, The Lancet.

[36]  U. Aguirre,et al.  Predictors of Hospital Admission Two Months after Emergency Department Evaluation of COPD Exacerbation , 2014, Respiration.

[37]  M. Martínez-García,et al.  Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. , 2009, Respiratory medicine.

[38]  Jiachun Lu,et al.  COPD in Chinese nonsmokers , 2009, European Respiratory Journal.

[39]  A. Puttanna,et al.  Systemic Effects of Inhaled Corticosteroids: An Overview , 2014, The open respiratory medicine journal.

[40]  Alvar Agusti,et al.  Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. , 2015, Chest.

[41]  S. Bourke,et al.  Predicting outcomes following hospitalization for acute exacerbations of COPD. , 2010, QJM : monthly journal of the Association of Physicians.

[42]  I. Stiell,et al.  Predictors of hospital admission for chronic obstructive pulmonary disease exacerbations in Canadian emergency departments. , 2009, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[43]  A. Viera Odds ratios and risk ratios: what's the difference and why does it matter? , 2008, Southern medical journal.

[44]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[45]  T. Gislason,et al.  Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression , 2005, European Respiratory Journal.

[46]  J. Soriano,et al.  Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. , 2012, Chest.

[47]  C. Montón,et al.  Causes of Death and Risk Factors for Mortality in Patients With Severe Chronic Obstructive Pulmonary Disease , 2009 .

[48]  M. R. Siddiqui,et al.  Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .

[49]  C. Donner,et al.  GOLD severity stratification and risk of hospitalisation for COPD exacerbations. , 2008, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[50]  Dave Singh,et al.  Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 , 2012, European Respiratory Journal.

[51]  G. Donaldson,et al.  COPD exacerbations · 1: Epidemiology , 2006, Thorax.

[52]  J. Real,et al.  Causas de muerte en pacientes con EPOC grave. Factores pronósticos , 2009 .

[53]  G. Cesana,et al.  The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients , 2014, PloS one.

[54]  Katayoon Bahadori,et al.  Risk factors of hospitalization and readmission of patients with COPD exacerbation – systematic review , 2007, International journal of chronic obstructive pulmonary disease.